公开(公告)号：US11975072B2

公开(公告)日：2024-05-07

申请号：US16632649

申请日：2018-07-20

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE DE LILLE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE LORRAINE ,  INSTITUT PASTEUR DE LILLE ,  CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE

Inventor： Henri Azais ,  Pierre Collinet ,  Nadira Delhem-Fellahi ,  Olivier Morales ,  Serge Mordon ,  Céline Frochot ,  Régis Vanderesse ,  Aurélie Stallivieri

IPC: A61K41/00 ,  A61K47/54 ,  A61K49/00 ,  A61P35/00

CPC classification number: A61K41/0071 ,  A61K47/546 ,  A61K49/0052 ,  A61P35/00

Abstract: The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.

公开(公告)号：US20240139249A1

公开(公告)日：2024-05-02

申请号：US18483323

申请日：2023-10-09

Applicant: ETABLISSEMENT FRANCAIS DU SANG ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON ,  UNIVERSITE DE FRANCHE COMTE

Inventor： Christophe FERRAND ,  Marina DESCHAMPS ,  Fabrice LAROSA

IPC: A61K35/17 ,  A61P35/02 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28 ,  C12N5/10 ,  C12N15/85

CPC classification number: A61K35/17 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/7155 ,  C07K16/2866 ,  C12N5/10 ,  C12N15/85 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33

Abstract: The present invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody fragment which includes a anti-IL-1RAP binding domain, polypeptides encoded by this nucleic acid molecule, isolated chimeric antigen receptor (CAR) molecule comprising such an antibody or antibody fragment, a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising this vector. The present invention is also relative to the use of this T cell (autologous or allogeneic) expressing a CAR molecule to treat a proliferative disease in a mammal.

公开(公告)号：US20240122938A1

公开(公告)日：2024-04-18

申请号：US17768675

申请日：2020-10-28

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE COTE D'AZUR

Inventor： Robert BALLOTTI ,  Corine BERTOLOTTO-BALLOTTI

IPC: A61K31/5377 ,  A61K31/519 ,  A61P35/00

CPC classification number: A61K31/5377 ,  A61K31/519 ,  A61P35/00

Abstract: The present invention relates to a compound ABT-263 or a derivative thereof for use in the treatment of uveal melanoma and/or uveal melanoma resistant. Inventors provide evidence that ABT-263 displays clear antiproliferative and proapoptotic activities in metastatic uveal melanoma cells both in vitro and in vivo. They also demonstrated that ABT-263 effect is accompanied with the activation of the ER stress response pathway that exerts cytoprotective effect. Blocking ER stress enhanced ABT-263 killing efficacy. The combination of ABT-263 with PERK inhibition synergistically reduced the survival rate of primary uveal melanoma cells.

公开(公告)号：US11946909B2

公开(公告)日：2024-04-02

申请号：US16971763

申请日：2019-02-21

Applicant: Assistance Publique-Hopitaux de Paris ,  Centre National de la Recherche Scientifique (CNRS) ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Universite De Paris ,  Ecole Nationale Superieure de Chimie de Paris

Inventor： Hugo Salmon ,  Rabah Gahoual ,  Nathalie Mignet ,  Pascal Houze

IPC: G01N30/00

CPC classification number: G01N30/0005 ,  G01N2030/003

Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the membrane (10).

公开(公告)号：US20240100048A1

公开(公告)日：2024-03-28

申请号：US18532790

申请日：2023-12-07

Applicant: INSTITUT PASTEUR ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： Rosa BARREIRA DA SILVA ,  Matthew ALBERT

IPC: A61K31/4985 ,  A61K31/40 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/522 ,  A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/4985 ,  A61K31/40 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/522 ,  A61K35/17 ,  A61K39/001129 ,  A61K45/06 ,  A61P35/00 ,  A61K31/403

Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.

公开(公告)号：US11939577B2

公开(公告)日：2024-03-26

申请号：US17279206

申请日：2019-09-24

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： Liliane Massade ,  Charbel Massaad ,  Susan Boutary ,  Giorgia Maria Laura Urbinati ,  Patrick Couvreur ,  Didier Desmaële

IPC: C12N15/113 ,  A61K9/51 ,  A61K45/06 ,  A61K47/69

CPC classification number: C12N15/113 ,  A61K9/5123 ,  A61K45/06 ,  A61K47/6929 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/351 ,  C12N2320/32

Abstract: The present invention relates to antisense RNAs targeting PMP22 and able to inhibit from 40% to 60% the expression of PMP22 in the cells and a pharmaceutical composition comprising thereof. The antisense RNAs are preferably siRNA and are preferably provided in the form of nanoparticles. The present invention also relates to the use of these antisense RNAs targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease.

公开(公告)号：US20240096495A1

公开(公告)日：2024-03-21

申请号：US18510726

申请日：2023-11-16

Applicant: UNIVERSITE DE STRASBOURG ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Inventor： DOMINIQUE BAGNARD ,  AURORE FERNANDEZ ,  LAURENT JACOB ,  JUSTINE FRITZ

IPC: G16H50/20 ,  C12Q1/6886 ,  G16H20/10 ,  G16H50/50

CPC classification number: G16H50/20 ,  C12Q1/6886 ,  G16H20/10 ,  G16H50/50 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present invention provides a powerful tool to identify personalized therapeutic strategies. In particular, the invention provides methods for determining therapeutically targetable dominant signaling pathways in a cancer sample from a subject affected with a solid cancer, determining a treatment protocol for the subject, selecting a subject for a therapy, determining whether the subject is susceptible to benefit from a therapy, predicting clinical outcome of the subject, treating the subject and/or predicting the sensitivity of a solid cancer to a therapy.

公开(公告)号：US20240092858A1

公开(公告)日：2024-03-21

申请号：US18255951

申请日：2020-12-08

Applicant: SORBONNE UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)

Inventor： Christina Zeitz ,  Deniz Dalkara ,  Juliette Varin ,  Isabelle Audo ,  Serge Picaud ,  José-Alain Sahel

IPC: C07K14/705 ,  A61K48/00 ,  A61P27/02 ,  C12N15/86

CPC classification number: C07K14/70503 ,  A61K48/0058 ,  A61P27/02 ,  C12N15/86 ,  C12N2750/14143 ,  C12N2830/008 ,  C12N2830/48

Abstract: The present invention relates to an expression cassette allowing expression of a functional LRIT3 protein in mammal eyes; said expression cassette is inserted in an expression vector, preferably an adeno-associated virus (AAV); accordingly, the present invention further relates to a recombinant adeno-associated virus (AAV) vector carrying a nucleic acid sequence encoding a normal LRIT3 gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells, a pharmaceutically acceptable composition comprising such a recombinant AAV vector and to its use for the treatment of congenital stationary night blindness

公开(公告)号：US11926829B2

公开(公告)日：2024-03-12

申请号：US17166377

申请日：2021-02-03

Applicant: ASSOCIATION ISNTITUT DE MYOLOGIE ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  SORBONNE UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Inventor： Marc Bitoun ,  Delphine Trochet ,  Bernard Prudhon

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N2310/14 ,  C12N2320/34 ,  C12Y306/05005

Abstract: The invention relates to an allele specific siRNA able to silence the expression of only one allele of a heterozygous DNM2 gene, for treating diseases caused by heterozygous mutation and/or overexpression of Dynamin 2.

公开(公告)号：US20240067942A1

公开(公告)日：2024-02-29

申请号：US18266282

申请日：2021-12-09

Applicant: GENETHON ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE D'EVRY VAL D'ESSONNE ,  UNIVERSITE PARIS-SACLAY

Inventor： MARIO AMENDOLA ,  MARINE LAURENT ,  GIULIA PAVANI

IPC: C12N9/20 ,  A61P3/00 ,  C12N5/0789 ,  C12N15/86

CPC classification number: C12N9/20 ,  A61P3/00 ,  C12N5/0647 ,  C12N15/86 ,  C12N2710/10041 ,  C12Y301/01013

Abstract: The present invention relates to variants of lysosomal acid lipase (LAL) and uses thereof.